Table 1 Cohort study vaccine effectiveness against hospitalisations, emergency department attendances and community consultations for RVGE or AGE
Study | Country | Vaccine | Age-group (months) | Cohort year | Vaccinated (N) | Incidence among unvaccinated (N) | Vaccine effectiveness (95% CI) | ||
|---|---|---|---|---|---|---|---|---|---|
Dose | Incidence | Unadjusted | Adjusted | ||||||
Hospitalisation for RVGE | |||||||||
Eberly et al. 2011 [23] | USA | RV1 and RV5 | <60 | All | 1 | NR | 581/237660 | 86 (78-91) | NR |
1 or more | 42/140213 | 88 (83-91) | NR | ||||||
2 RV1 / 3 RV5 | 11/NR | 90 (82-95) | NR | ||||||
Panozzo et al. 2014* [30] | USA | RV1 and RV5 | 8-20 | 1 | 1 or more | 3/68380 | 60/64929 | NR | 87 (58-96) |
2 | 23/175890 | 91/91051 | NR | 87 (80-92) | |||||
3 | 22/250035 | 74/61218 | NR | 92 (87-95) | |||||
4 | 8/254377 | 13/41946 | NR | 90 (75-96) | |||||
Hospitalisation and ED attendance for RVGE | |||||||||
Wang et al. 2010 [20] | USA | RV5 | <36 | All | 3 | 0/7700 | 23/5831 | 100 (87-100) | NR |
Wang, 2013 [21] | USA | RV5 | <36 | All | 1 | 2/5019 | 11/3343 | 88 (45-99) | NR |
All | 2 | 1/5886 | 13/4432 | 94 (61-100) | NR | ||||
Hospitalisation and ED attendance for AGE | |||||||||
Wang et al. 2010 [20] | USA | RV5 | <36 | All | 3 | 87/7700 | 160/5831 | 59 (46-69) | 59 (47-68) |
Wang, 2013 [21] | USA | RV5 | <36 | All | 1 | 53/5019- | 63/3343 | 44 (18-62) | 46 (22-63) |
All | 2 | 78/5886 | 98/4432 | 40 (18-56) | 39 (16-55) | ||||
Hospitalisation for AGE | |||||||||
Panozzo et al. 2014* [30] | USA | RV1 and RV5 | 8-20 | 1 | 1 or more | 142/68378 | 271/64928 | NR | 22 (3-37) |
2 | 413/175765 | 317/90882 | NR | 40 (30-48) | |||||
3 | 512/249838 | 300/61136 | NR | 56 (49-62) | |||||
4 | 398/254232 | 109/41888 | NR | 41 (27-53) | |||||
Community consultations for RVGE | |||||||||
Wang et al. 2010 [20] | USA | RV5 | <36 | All | 3 | 1/7700 | 20/5831 | 96 (76-100) | NR |
Wang et al. 2013 [21] | USA | RV5 | <36 | All | 1 | 0/5019 - | 7/3343 | 100 (54-100) | NR |
All | 2 | 4/5886 | 5/4432 | 40 (<0-88) | NR | ||||
Community consultations for AGE | |||||||||
Fontes-Vieira et al. 2011 [17]** | Brazil | RV1 | <12 | 1 | 2 | 87/100 | 84/100 | -4 (-16 to 8) | NR |
2 | 52/100 | 42/100 | -24 (-67 to 8) | NR | |||||
Muhsen et al. 2011 [18] | Israel | RV1 | <12 | All | 1 | 153/716 | 8801/18591 | 54 (47-60) | NR |
All | 2 | 1605/6870 | 50 (47-52) | NR | |||||
Nolan et al. 2012 [19]† | USA | RV5 | <24 | 1 | 1 or more | NR | NR | NR | 28 (-21 to58) |
1 | NR | NR | NR | 22 (-13 to 46) | |||||
2 | NR | NR | NR | 37 (-37 to 71) | |||||
Wang et al. 2010 [20] | USA | RV5 | <36 | All | 3 | 1321/7700 | 1377/5831 | 27 (22-33) | 28 (22-33) |
Wang et al. 2013 [21] | USA | RV5 | <36 | All | 1 | 651/5019 | 521/3343 | 17 (6-26) | 17 (7-26) |
All | 2 | 774/5886 | 847/4432 | 31 (24-38) | 28 (21-35) | ||||